Literature DB >> 8086775

Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution.

W Korte1, A Feldges.   

Abstract

We describe a patient with congenital afibrinogenemia who showed elevated prothrombin activation fragments (F1 + 2) indicating increased thrombin formation. This finding was unexpected since it has hitherto been thought that patients with congenital hypo- or afibrinogenemia have no evidence of increased utilization or accelerated consumption of coagulation factors. No other possible reasons for the elevation of F 1 + 2 were found. Upon fibrinogen substitution F1 + 2 decreased and were again increasing when fibrinogen concentration in plasma fell to very low levels. These findings raise the question of whether increased thrombin formation should be understood as a compensatory mechanism in congenital afibrinogenemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086775     DOI: 10.1007/bf00252836

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  5 in total

1.  Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination.

Authors:  H D Bruhn; J Conard; M Mannucci; J Monteagudo; H Pelzer; J C Reverter; M Samama; A Tripodi; C Wagner
Journal:  Thromb Haemost       Date:  1992-10-05       Impact factor: 5.249

2.  Influence of aging on the activity of the hemostatic system: prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years.

Authors:  Y Cadroy; D Pierrejean; B Fontan; P Sié; B Boneu
Journal:  Nouv Rev Fr Hematol       Date:  1992

3.  Fibrin assembly in human plasma and fibrinogen/albumin mixtures.

Authors:  J Torbet
Journal:  Biochemistry       Date:  1986-09-09       Impact factor: 3.162

4.  Coagulation activation following estrogen administration to postmenopausal women.

Authors:  Y G Caine; K A Bauer; S Barzegar; H ten Cate; F M Sacks; B W Walsh; I Schiff; R D Rosenberg
Journal:  Thromb Haemost       Date:  1992-10-05       Impact factor: 5.249

5.  The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation.

Authors:  K A Bauer; R D Rosenberg
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

  5 in total
  4 in total

Review 1.  Thrombosis in Inherited Fibrinogen Disorders.

Authors:  Wolfgang Korte; Man-Chiu Poon; Alfonso Iorio; Michael Makris
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

2.  Primed to Understand Fibrinogen in Cardiovascular Disease.

Authors:  Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01       Impact factor: 8.311

Review 3.  Treatment of congenital fibrinogen deficiency: overview and recent findings.

Authors:  Konstantinos Tziomalos; Sofia Vakalopoulou; Vassilios Perifanis; Vassilia Garipidou
Journal:  Vasc Health Risk Manag       Date:  2009-10-12

Review 4.  Integrating platelet and coagulation activation in fibrin clot formation.

Authors:  Frauke Swieringa; Henri M H Spronk; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Res Pract Thromb Haemost       Date:  2018-05-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.